American Journal of Hematology
Nov 10, 2025, 10:37
Should Transferrin Saturation Guide HFE-Hemochromatosis Therapy?
American Journal of Hematology shared on X:
“In HFE-hemochromatosis, transferrin saturation above ~75% suggests harmful non-transferrin-bound iron levels. Due to assay limits for NTBI, monitoring TSAT levels during maintenance therapy may help and should guide care until accurate NTBI tests exist.”
Title: Should Serum Transferrin Saturation Be Included as a Therapeutic Target in Addition to Serum Ferritin in Treating HFE-Hemochromatosis?
Authors: Nils Thorm Milman, Christina Ellervik
Read the full article here.
Stay updated with Hemostasis Today.
-
Jun 4, 2026, 13:38Denis Oduor: The Role of Expectant Fathers in Saving Mothers and Newborns
-
Jun 4, 2026, 13:36Mohammad Reza Moghaddasnejad: Platelet Activation as a Key Driver of Breast Cancer Progression
-
Jun 4, 2026, 13:31Fredrick Chalinga: Microcytic Anemia Does Not Always Mean Iron Deficiency
-
Jun 4, 2026, 13:23How Access to Care Changed One Life – WFH
-
Jun 4, 2026, 13:16Muhammad Usman Arshad: Meta-Analysis Supports Expanding Role of DOACs in Cancer-Associated Thromboembolism
-
Jun 4, 2026, 12:59Dual Prognostic Significance of P2RY12 in Antithrombotic-Treated STEMI – JTH
-
Jun 4, 2026, 12:43Beth Wallace: Raising Awareness of Hereditary Haemochromatosis
-
Jun 4, 2026, 11:57José María Bastida Bermejo: IPDs Help to Better Understand Platelet Biogenesis and Function
-
Jun 4, 2026, 11:07Cristina Pecorilla: PSG6 and A New Approach to Cancer-Associated Thrombosis